All In Biotech

Drug Trial Radar · NCT03694197

Long Term Safety Study of PRALUENT

Long Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enrolled in the Neurocognitive Function Trial

Last checked: Nov 20, 2026Latest source record: Jun 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

1,389

Actual

Start

Sep 28, 2018

Primary completion

Apr 8, 2020

Study completion Apr 8, 2020

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Sanofi
First posted
Oct 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study was to evaluate the long term safety of PRALUENT in participants with heterozygous familial hypercholesterolemia (heFH) or non-familial hypercholesterolemia (FH) participants at high or very high cardiovascular risk who completed the neurocognitive function study R727-CL-1532 (NCT02957682). The secondary objectives of the study were: * To evaluate the effect of PRALUENT on low-density lipoprotein cholesterol (LDL-C) * To evaluate the effect of PRALUENT on other lipid parameters * To evaluate the effect of PRALUENT on gonadal steroid hormones

Conditions

  • Heterozygous Familial Hypercholesterolemia
  • Non-familial Hypercholesterolemia

Interventions

  • PraluentDrug

    Subcutaneous (SC) administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AE) After First Administration of Study Drug Through the Last Dose of Study Drug Plus 2 WeeksTime frame: After first administration of study drug through the last dose of study drug plus 2 weeks, up to 80 weeks

Locations

123 sites in 6 countries. Site status is shown where the registry gives one.

  • Regeneron Research Site

    Auburn, Alabama

  • Regeneron Research Site

    Mobile, Alabama

  • Regeneron Research Site

    Beverly Hills, California

  • Regeneron Research Site

    Los Gatos, California

  • Regeneron Research Site

    North Hollywood, California

  • Regeneron Research Site

    Port Hueneme, California

  • Regeneron Research Site

    Aurora, Colorado

  • Regeneron Research Site

    Colorado Springs, Colorado

  • Regeneron Research Site

    Lake Worth, Florida

  • Regeneron Research Site

    Miami Springs, Florida

  • Regeneron Research Site

    Champaign, Illinois

  • Regeneron Research Site

    Evansville, Indiana

  • Regeneron Research Site

    Indianapolis, Indiana

  • Regeneron Research Site

    Ames, Iowa

  • Regeneron Research Site

    Iowa City, Iowa

  • Regeneron Research Site

    Waterloo, Iowa

  • Regeneron Research Site

    Newton, Kansas

  • Regeneron Research Site

    Louisville, Kentucky

  • Regeneron Research Site

    Bangor, Maine

  • Regeneron Research Site

    Baltimore, Maryland

  • Regeneron Research Site

    Oxon Hill, Maryland

  • Regeneron Research Site

    Olive Branch, Mississippi

  • Regeneron Research Site

    Washington, Missouri

  • Regeneron Research Site

    Buffalo, New York

  • Regeneron Research Site

    New Hyde Park, New York

  • Regeneron Research Site

    Cary, North Carolina

  • Regeneron Research Site

    Charlotte, North Carolina

  • Regeneron Research Site

    Charlotte, North Carolina

  • Regeneron Research Site

    Greensboro, North Carolina

  • Regeneron Research Site

    Hickory, North Carolina

  • Regeneron Research Site

    Raleigh, North Carolina

  • Regeneron Research Site

    Rocky Mount, North Carolina

  • Regeneron Research Site

    Salisbury, North Carolina

  • Regeneron Research Site

    Statesville, North Carolina

  • Regeneron Research Site

    Wilmington, North Carolina

  • Regeneron Research Site

    Winston-Salem, North Carolina

  • Regeneron Research Site

    Cincinnati, Ohio

  • Regeneron Research Site

    Cleveland, Ohio

  • Regeneron Research Site

    Dayton, Ohio

  • Regeneron Research Site

    Charleston, South Carolina

Showing 40 of 123 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.